Waddill William D. sold $969K of PTGX
Waddill William D. sold 9,000 shares of Protagonist Therapeutics, Inc (PTGX) at $107.68 ($0.97M total) on 2026-06-10 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest disclosed fact is the director’s open-market sale of 9,000 shares at $107.68 on 2026-06-10, with remaining holdings of 7,825 shares after the trade.
Market read
Insider selling can influence near-term sentiment, but 10b5-1 structure usually limits interpretive impact.
What to watch
Traders may focus more on whether insider selling accelerates across multiple filings or coincides with other company-specific catalysts (trials, financing, guidance), which are not present here.
Background
The article is an SEC Form 4 insider transaction disclosure for Protagonist Therapeutics (PTGX).
Ticker impact
Director Waddill William D. sold 9,000 PTGX shares in an open-market transaction for ~$969K under a pre-arranged 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
The filing is an SEC Form 4 insider sale with explicit 10b5-1 pre-arrangement, which typically reduces interpretive value versus discretionary selling.
Market effects
No clear sector read-through from a single director 10b5-1 sale.
None indicated.
None indicated.
Counterpoint
Because the sale is 10b5-1 pre-arranged, it could be mechanically scheduled and not reflect bearish views; any dip may be overdone.
Key entities
- issuerProtagonist Therapeutics, Inc
Company whose shares were sold by a director under a 10b5-1 plan.
- insiderWaddill William D.
Director who executed the open-market sale disclosed on Form 4.
